Back to Search
Start Over
Clinical Experience with Oral Tofacitinib in a Patient with Alopecia Areata Universalis and Rheumatoid Arthritis.
- Source :
-
International journal of trichology [Int J Trichology] 2020 Jul-Aug; Vol. 12 (4), pp. 188-190. Date of Electronic Publication: 2020 Sep 19. - Publication Year :
- 2020
-
Abstract
- Alopecia areata (AA) is a chronic and autoimmune disease frequently characterized by a challenge management between dermatologists. At present, JAK-inhibitors have demonstrated encouraging results in AA treatment. Therefore, this study reports a case of alopecia universalis in a patient with rheumatoid arthritis (RA), whose methotrexate therapy shown unsatisfactory response in RA control. After the introduction of 10 mg (oral route) per day of tofacitinib, a JAK-inhibitor, an improvement of almost 50% in severity alopecia tool score occurred with maintained response even after 3 months of medication suspension. From this time, we corroborate the effectiveness of JAK-inhibitors presented in the scientific literature. In addition, we inquiry the real impact of methotrexate on JAK-start signaling inhibition in AA pathophysiology.<br />Competing Interests: There are no conflicts of interest.<br /> (Copyright: © 2020 International Journal of Trichology.)
Details
- Language :
- English
- ISSN :
- 0974-7753
- Volume :
- 12
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- International journal of trichology
- Publication Type :
- Report
- Accession number :
- 33376289
- Full Text :
- https://doi.org/10.4103/ijt.ijt_107_20